Picture the world as it was in 1983, the year BioTechniques launched. Ronald Reagan was in the White House. Americans thrilled to the adventures of Luke Skywalker and Darth Vader in "Return of the Jedi" and took their first steps into the digital age with the then two-year-old IBM PC.
On the scientific front, DNA sequencing was still relatively new. The polymerase chain reaction didn't yet exist-it was still just a brainstorm inventor Kary Mullis had on a California highway that wouldn't see print until 1985. Meanwhile, cell biologists were capturing ever more beautiful images with their microscopes, but their efforts were constrained by the then insurmountable diffraction limit.
Not surprisingly, life science today bears little resemblance to the way it was practiced three decades ago. Whole-genome sequencing is now routine, as is PCR. And microscopists have breached the once inviolable diffraction limit, taking pictures of cellular structures with unprecedented resolution.
To gain some perspective on the past 30 years in life science technology development, we spoke with key innovators in the fields of DNA sequencing, PCR, and microscopy. Their insights are both interesting and informative, a history lesson from the developers who changed the way we work in the lab.
Sequencing: Moving Up By Scaling Down
In 1983 George Church was nearing the end of his graduate work at Harvard University. He had matriculated in 1977, and that same year joined the lab of DNA sequencing pioneer (and future Nobel laureate) Walter Gilbert.
From the beginning, Church was focused on genome sequencing. In 1974, while still a Duke University undergraduate, he manually keyed in and folded the structure of every then-known tRNA sequence. "I started hoping that every person could afford to see their own DNA sequence, " he writes on his web site. Graduating in 1984, his thesis described "the first methods for direct genome sequencing, molecular multiplexing [and] barcoding. "
That year, Church participated in a meeting at Alta, Utah that would launch the Human Genome Project (HGP). At the time, the only technology capable of decoding the human genome was Sanger dideoxy sequencing, and as the HGP took shape, some argued that the way forward was to ramp up existing technology. But Church argued for a different solution.
"I felt that $3 billion was an unacceptable amount of money for Sanger-based sequencing. " He would spend much of the next two decades trying to find a less costly alternative. And he wasn't the only one.
Jonathan Rothberg ran his first sequencing reaction as an undergrad at Carnegie Mellon University in 1983. He entered Yale University as a doctoral student two years later, and by the time he graduated in 1991 had managed to completely sequence a neuronal gene called slit-9000 bases decoded in six years.
Despite the slow pace, it was apparent even then that the burgeoning field of genomics promised to transform medical science, and in 1991 Rothberg founded CuraGen, a biotech firm devoted to mining the human genome for drug targets and insights into complex diseases. By 1999, CuraGen was a $5 billion, publicly traded company, and Rothberg was its CEO. "I thought I was on top of the world. "
Then his son, Noah, was born and was having difficulty breathing. The "consensus" human genome that was being assembled at the time was of little immediate value for Noah. "I realized that I wasn't as interested in the human genome; I was really interested in my son Noah' s genome. And that for me was my first introduction to personal genomics. "
Up until then, genomics had taken what Rothberg calls a "Henry Ford approach" to sequencing, "where you just set up an existing technology, but you set it up as an assembly line. " That strategy, implemented at places like the Broad Institute in Cambridge, Massachusetts and the Sanger Institute in the UK, is difficult to scale to the point where sequencing an individual genome is financially and temporally practical.
So Rothberg, like Church, was looking for a paradigm shift, which he found on the cover of a computer magazine that happened to be on his desk. That cover described a new Intel Pentium chip. "We've been doing it wrong, " he thought. "It' s not about Henry Ford, it' s about [Intel co-founder] Gordon Moore. "
What needed to happen was to scale not up but down. "We needed to miniaturize sequencing. " Over the next two weeks-the time allotted for his paternity leave-Rothberg hashed out a new design based on cloning by limiting dilution and a solid-phase version of pyrosequencing, a technique that at time was used only for calling SNPs. The result was the massively parallel sequencing-by-synthesis strategy that was the foundation for 454 Life Sciences.
Church also realized the key to cheaper sequencing was miniaturization, and had spent much of the previous two decades testing and developing strategies to get there. One method called multiplex sequencing, which was developed in 1988, featured several characteristics of modern next-generation sequencing. DNA sequences were immobilized on a flat surface and then subjected to many alternating cycles of probing and capturing the data using a digital camera. Church had also developed a strategy in which tiny pools of identical molecules are created in situ by a polymerase-so-called polymerase-generated colonies, or "polonies. "
"I try to familiarize myself with many different technologies, " Church says, describing himself as "constantly on the prowl for combinations that I could match up with sequencing human genomes, because clearly that cost was off by a million at least. "
In 2005, Church and his team rolled his various ideas into a new sequencing-by-ligation strategy that they published in the journal Science (1). That same week, Rothberg' s team at 454 described their strategy in Nature (2).
According to Rothberg, it takes more than good sequencing technology to produce a successful sequencing strategy. There' s also the ability to eliminate the DNA cloning steps that remain so critical in Sanger-based approaches. "You really have to crack both problems to make it into a successful technology, " he says. "Sequencing was half the problem, sample prep was the other. "
Both groups solved the problem the same way: by making libraries on-the-fly on the surface of micron-sized beads, arraying and immobilizing them on a planar surface, and applying cycles of sequencing chemistry in situ. Then, instead of running gels or capillaries, they imaged the array over and over again, using computers to sort out the data. It' s a strategy that is now used in broad strokes by every major sequencing vendor on the market.
Since 
Making PCR Quantitative
1983 was also a banner year for Kent Vrana.
Vrana, the Elliot S. Vesell Professor and Chair of Pharmacology at Penn State College of Medicine in Hershey, Pennsylvania (and a member of the BioTechniques editorial board), earned his PhD that year. His thesis was biochemical, but in 1983, he says, "molecular biology was just breaking, " so he took a postdoc to learn the new technology.
Moving on to West Virginia University, he started his own lab studying transcript abundance. At the time, Vrana says, that meant Northern blotting. But the technique wasn't easy. "Very labor intensive, very difficult to quantify, [and] we were using a lot of radioactivity to do this. " PCR, Vrana says, had an immediate impact. "It cut the time to analyze RNA down by probably a factor of five. "
But at the start, the technique wasn't really quantitative. PCR, in its original form, was an endpoint assay, a plus/minus readout where data are interpreted after the reaction has finished using gel electrophoresis. Band size indicates a positive or negative reaction, yet band intensity has little quantitative value because the reaction often isn't linear. To circumvent that problem, researchers like Vrana had to take extreme measures, such as constructing standard curves and tediously titrating cycle numbers.
This all changed in 1993. Russell Higuchi, at Roche Molecular Systems, and colleagues described a method for real-time quantitative PCR (qPCR). This method used an intercalating dye (ethidium bromide) and a CCD camera to record reaction progress as cycling proceeded, producing a reliably quantitative analysis of PCR amplification.
Other methods soon followed. SYBR Green supplanted ethidium, and other strategies were introduced, too, most notably Life Technologies' popular TaqMan chemistry, which uses a fluorescently labeled oligonucleotide probe to assess target abundance, rather than a non-specific DNA-binding dye. Vrana became an early adopter. "I was bright enough to see…the power with which it could be used, " he says. Yet PCR was not just about RNA quantitation. Vrana also used it for creating mutants, genetic analysis, validation of microarray data, and more. "It has turned out to be a bedrock in the field, " he says.
Today, qPCR is a hugely popular PCR variant, and RNA quantification is among its most common applications. In 2008 Vrana co-authored a review on PCR' s 25th anniversary that tracked the number of qPCR papers over time (3) . The figure resembles a typical qPCR amplification curve, he says. "They could be superimposed on each other. "
Of course, researchers knew long before the invention of qPCR that dyes such as ethidium bromide can bind DNA. And they also knew about PCR' s quantitative limitations. Why, then, did it take so long for someone to put the two together?
"It truly was an engineering solution, " he says. "I don't think people understood the potential for real-time quantitative PCR. To think back on it now, the draconian things we used to do in terms of quantifying amplicons on ethidium bromide gels-I'm just stunned that we would do that. "
Breaking the Diffraction Barrier
About the time that Higuchi was introducing the world to qPCR, Stefan Hell was preparing to upend the world of microscopy.
At the end of the 1980s, Hell was a doctoral student at the University of Heidelberg. Though his interests lay in more fundamental aspects of physics, his thesis advisor directed him towards an applied project, studying the application of confocal microscopy to inspect photolithographic structures. It wasn't where Hell wanted to go. As he contemplated the fundamentals of light microscopy, Hell began to think about the so-called diffraction (or Abbe) limit, which says two objects cannot be distinguished under a light microscope if they are closer than half the wavelength of light used to illuminate them.
That limitation is a function of the properties of light and lenses, and since the invention of the microscope it has been practically inviolable. And indeed, it is inviolable-the wave properties of light mean optics can only be so precise and can focus only so sharply. But that doesn't mean it isn't possible to make the limit irrelevant.
Hell started exploring "molecular transitions, " the ability of fluorescent molecules to occupy one of two states, active or silent. Consulting textbooks on everything from quantum optics to nuclear physics, he noticed a phenomenon he had learned about as a first-year student: stimulated emission.
"If you realize that you want to keep things dark, if you're trained as a physicist, then you know the most fundamental way of turning a fluorophore off is to instantly send it down to the ground state by [using] a beam inducing stimulated emission, " he says.
Hell worked out the mathematics of this ideawhich he now calls "the on/off game"-in 1993 and published his proposal in 1994. He then spent the next half-decade trying to convince the scientific world (and funding agencies) that he was right. He finally got the money and lab space to implement his idea in 1998, and demonstrated the technique works in a pair of papers in 1999 and 2000 (4, 5) .
The technique he invented is called STED (stimulated emission depletion) microscopy and uses two lasers to improve resolution from about 200 nm to 50 nm. The sharply focused
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excitation beam activates all the fluorophores in a diffraction-limited spot under the microscope. A second stimulated emission laser overlaid on the excitation beam causes fluorophores in the overlap region to stay dark. By altering the intensity of the second laser, he could raise or lower the resolution, theoretically down to the size of a single molecule. "You can break the diffraction barrier without having to break diffraction, " he says.
The result was the first so-called super-resolution technique. Alternative strategies followed a few years later, especially PALM and STORM, as well as another Hell-lab invention, RESOLFT, which derives multiple states from the cis-trans isomerization of fluorescent molecules.
Regardless of their acronyms, these techniques all rely on the same fundamental phenomenon, says Hell, the ability of fluorophores to assume two different states, making adjacent nanoscale features distinguishable.
"The on/off transition, the fact that not all the molecules residing within a 200-nm zone are capable of sending light back, this has been the essential element for overcoming the diffraction barrier, " Hell says.
Super-resolution microscopy is having "a lasting impact" on the life sciences and basic biomedical research. But the power of two-state transitions isn't yet played out. Other molecules can adopt multiple states, too, including Ramanactive probes.
"I'm totally convinced that future generations will not see the light microscope just from a wave perspective, but also from a state perspective, " he says, a totally different perspective from when he started thinking about the problem in 1983. 
